Advertisement
Document › Details
Vividion Therapeutics, Inc.. (11/23/20). "Press Release: Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer". San Diego, CA.
Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer. Mr. Hatfield brings more than 35 years of successful industry leadership to Vividion, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies.
“Jeff is a highly accomplished industry leader who can help us deliver the full potential of Vividion’s differentiated discovery platform,” said Richard Heyman, Ph.D., chairman of the Vividion board of directors. “Jeff brings decades of relevant experience, including building platform-based companies, advancing first-in-class programs, executing financing strategies to drive near and long-term value growth, negotiating innovative business development partnerships and strategic transactions, and cultivating collaborative, high-performance cultures. The board is confident in Jeff’s ability to drive significant future growth, and we are thrilled to welcome him to the team.”
“Vividion is built on unprecedented insights into emerging and synergistic technologies, which together, create a powerful drug discovery platform with the potential to tremendously expand horizons for small molecule discovery – beyond what we consider possible today,” said Mr. Hatfield. “The company stands well positioned for success, with several rapidly advancing first-in-class programs in oncology and immunology, major pharmaceutical collaborations with BMS and Roche, a multi-year cash runway, and the significant backing of top-tier life science investors. I am excited to join this highly talented team as we work together to bring forward important new medicines that have the opportunity to extend and enhance the lives of millions of patients around the world.”
Among Mr. Hatfield’s many career leadership roles, he previously served as the CEO of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Earlier, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S . market access. Mr. Hatfield currently serves as chairman of the board of miRagen Therapeutics, Inc. and as a board member at aTyr Pharma. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School, University of Pennsylvania, and a B.S. from the Purdue University College of Pharmacy.
About Vividion
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. For more information, please visit www.vividion.com.
# # #
Contact:
Nick Veomett
media@vividion.com
(858) 257-1535
Record changed: 2023-06-05 |
Advertisement
More documents for Bayer (Group)
- [1] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
- [2] Bayer AG. (10/10/23). "Press Release: Bayer Invests 250 million USD in New Cell Therapy Manufacturing Facility in the U.S. [Not intended for US and UK Media]". Berlin....
- [3] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
- [4] Bayer AG. (9/21/23). "Press Release: Bayer to Collaborate with Hologic in Breast cancer Imaging [Not intended for U.S. and UK Media]". Berlin....
- [5] Bayer AG. (8/30/23). "Press Release: Strong Commitment to Modern Crop Protection Made in Europe. Bayer to Invest EUR 220 Million in New R&D Facility at Its Monheim Site". Monheim....
- [6] Bayer AG. (8/29/23). "Press Release: Gene Editing – Pairwise and Bayer Start New Five-year Multi-million Dollar Collaboration to Further Advance Short-stature Corn". Durham, NC & Monheim....
- [7] BlueRock Therapeutics LP. (8/23/23). "Press Release: BlueRock’s Phase I Study with Bemdaneprocel in Patients with Parkinson’s Disease Meets Primary Endpoint". Wuppertal....
- [8] Bayer AG. (8/22/23). "Press Release: Bayer Appoints Dr. Juergen Eckhardt as New Head of Pharmaceuticals Business Development & Licensing / Open Innovation". Berlin....
- [9] Lena Biosciences, Inc.. (8/7/23). "Press Release: Lena Biosciences Appoints Dr. Eckhard von Keutz to Its Business Advisory Board and Science Advisory Board"....
- [10] Bayer AG. (6/5/23). "Press Release: Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics [Not intended for U.S. and UK Media]". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top